HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Cognitive Claims Remain Online, But Closed Firm Off NAD Hook

This article was originally published in The Rose Sheet

Executive Summary

Legacy Labs closed its doors in March, but many claims challenged in a NAD review remain on websites it does not own. The Las Vegas firm says it will "make every effort to reach out to these website owners and request that the claims be removed immediately."

You may also be interested in...



Complaint Reminds CVS: No Support For Memory Claim In Fish Oil Study

A complaint filed by CSPI working with law firms in New York and Washington extends the dispute over cognitive claims for vitamin and supplement products from enforcement by FTC and FDA and questions from Congress to consumers' class action complaints.

Supplement Claims For Autism Treatment Could Ring A Bell At FTC

The firm that challenged Pursuit of Research’s claims and prompted a NAD review, NourishLife LLC, already incurred FTC enforcement about unsubstantiated claims that products treat childhood speech disorders.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel